Company Data
NewAmsterdam Pharma Company N.V.
Ticker
NAMS
Current Price
$31.71 -0.25%
Market Cap
$3.7B
Price Target
Refer to Report
Volume
2.0M
52wk Range
$17.63 - $42.205
Overview
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.